Growth hormone research is frequently discussed as though all approaches were equivalent. Mechanistically, exogenous hormone and endogenous secretagogues are quite different interventions.
Key Takeaways
- Growth hormone release is pulsatile and regulated by GHRH (stimulatory) and somatostatin (inhibitory).
- GHRH analogs and ghrelin receptor agonists act through separate receptors and are often studied together for that reason.
- Secretagogue approaches preserve feedback regulation; exogenous hormone bypasses it.
- Many downstream effects are mediated by IGF-1, primarily hepatic in origin.
- Amino Fuel Labs supplies these compounds strictly as laboratory research materials.
Axis Architecture
The hypothalamus releases GHRH, which stimulates pituitary somatotrophs to secrete growth hormone, and somatostatin, which suppresses it. The interplay produces a pulsatile secretion pattern rather than steady levels — pulses are larger during sleep and modulated by nutrition, exercise, and age.
Pulsatility is not incidental. Receptor responsiveness and downstream signaling differ between pulsatile and continuous exposure, which is a major reason secretagogue research is considered mechanistically distinct from continuous exogenous administration.
Two Receptor Families
| Class | Receptor | Representative research compounds |
|---|---|---|
| GHRH analogs | GHRH receptor | CJC-1295, tesamorelin, sermorelin |
| Ghrelin receptor agonists | GHS-R1a | Ipamorelin, GHRP-2, GHRP-6, hexarelin |
GHRH analogs amplify the physiological stimulatory signal. Ghrelin receptor agonists act through a distinct pathway originally identified via the hormone ghrelin, and they additionally suppress somatostatin tone in the models where this has been examined. Because the two mechanisms are separate, they are frequently studied in combination — a common pairing discussed in our growth hormone secretagogues overview.
Selectivity differs meaningfully within the ghrelin receptor group. Some compounds in this family show appreciable effects on other pituitary hormones or on appetite signaling in published work; others are described as more selective. Selectivity claims should be read as quantitative preferences, not absolutes.
IGF-1 as the Downstream Mediator
Much of growth hormone's anabolic signaling is mediated by insulin-like growth factor 1, produced largely in the liver in response to GH. IGF-1 is measured in research because it integrates GH exposure over time, whereas a single GH measurement captures only a point in a pulsatile curve.
That makes IGF-1 a useful surrogate — and a surrogate is what it is. Changes in IGF-1 are not automatically changes in body composition or function, a distinction covered in our common misreadings article.
Body Composition Findings in the Literature
The most rigorous human data in this area come from tesamorelin studies in a specific clinical population, where reductions in visceral adipose tissue were reported using imaging endpoints. Those findings are population-specific and indication-specific; they do not generalize to other groups or purposes.
For most other secretagogues, the evidence base is smaller, shorter, and more heterogeneous, and often relies on hormone-level endpoints rather than composition imaging.
Compound References
Research materials in this area include CJC-1295 with ipamorelin, tesamorelin, and HGH. All are supplied for laboratory research use only.
Frequently Asked Questions
Do secretagogues and exogenous GH produce the same effects? Not mechanistically. Secretagogues work through the endogenous axis and preserve feedback; exogenous hormone does not depend on pituitary output at all.
Why measure IGF-1 instead of GH? Because GH is pulsatile and a single measurement is unrepresentative, while IGF-1 reflects integrated exposure.
References
- Falutz J et al. Effects of tesamorelin on visceral adipose tissue. N Engl J Med / JAMA literature, 2007-2010.
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018.
- Veldhuis JD et al. Physiological regulation of pulsatile growth hormone secretion. Endocrine Reviews.
Amino Fuel Labs products are sold strictly for laboratory research use only. They are not intended for human or veterinary use, consumption, diagnosis, treatment, cure, or prevention of disease. This article is educational and is not medical advice.
